187 related articles for article (PubMed ID: 15647411)
1. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
Courtney R; Sansone A; Smith W; Marbury T; Statkevich P; Martinho M; Laughlin M; Swan S
J Clin Pharmacol; 2005 Feb; 45(2):185-92. PubMed ID: 15647411
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
5. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment.
Moton A; Krishna G; Ma L; O'Mara E; Prasad P; McLeod J; Preston RA
Curr Med Res Opin; 2010 Jan; 26(1):1-7. PubMed ID: 19886860
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis.
Mistry GC; Majumdar AK; Swan S; Sica D; Fisher A; Xu Y; Hesney M; Xi L; Wagner JA; Deutsch PJ
J Clin Pharmacol; 2006 Oct; 46(10):1128-38. PubMed ID: 16988201
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
Gupta SK; Kantesaria B; Glue P
Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease.
Stass H; Corkery K; Gribben D; Eldon MA
J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):191-9. PubMed ID: 21599533
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment.
Ravis WR; Reid S; Sica DA; Tolbert DS
J Clin Pharmacol; 2005 Jul; 45(7):810-21. PubMed ID: 15951471
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.
Krishna G; Parsons A; Kantesaria B; Mant T
Curr Med Res Opin; 2007 Mar; 23(3):545-52. PubMed ID: 17355736
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
[TBL] [Abstract][Full Text] [Related]
20. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.
Krishna G; Sansone-Parsons A; Kantesaria B
Curr Med Res Opin; 2007 Jun; 23(6):1415-22. PubMed ID: 17559737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
